Pharmacological bridge to cardiac transplantation: current limitations.
Addition of intravenous enoximone to sympathomimetic agents permits a rapid and drastic improvement in the clinical and hemodynamical condition of patients in cardiogenic shock referred for a mechanical bridge to transplantation. The present experience, based on the management of 52 patients, permits us to point out the current limitations of this pharmacological bridge: the rate of sudden death, the incompleteness of the physical rehabilitation of the patients, and the vanishing effect of intravenous enoximone.
Loisance
D Y
DY
Centre de Recherches Chirurgicales, CHU Henri Mondor, Faculté de Médicine, Creteil, France.
Deleuze
P H
PH
Houel
R
R
Benvenuti
C
C
el Sayed
A
A
Mazzucotelli
J P
JP
Tarral
A
A
Saal
J P
JP
Cachera
J P
JP
D000328:Adult; D001243:Assisted Circulation; D002315:Cardiopulmonary Bypass; D002423:Cause of Death; D004334:Drug Administration Schedule; D017335:Enoximone / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D016027:Heart Transplantation / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012151:Resuscitation
D017335:Enoximone